



FINAL  
OVARIAN CANCER COMMITTEE  
THURSDAY, OCTOBER 18, 2018, 8:00AM-9:30AM  
AMPHITHEATRE, KLINIKUM DER UNIVERSITAT MUENCHEN, DEPARTMENT OF GYNECOLOGY AND OBSTETRICS,  
CAMPUS INNENSTATDT, MAISTR. 11, MUNCHEN  
CHAIR: A.GONZALEZ CO-CHAIR: AIKOU OKAMOTO  
HARMONIZATION LIAISONS: LEVIN (OPS); EMBLETON (STATS)  
*PLEASE SIGN-IN ON ATTENDANCE FORMS*

### AGENDA

Welcome & Introductions: Gonzalez

COI Declarations

Approval of Minutes/Report: May 2018 (posted on GCI website)

Motion: \_\_\_\_\_ Seconded: \_\_\_\_\_

Closed/Published trials: (Maximum 5 minutes) Gonzalez

Ongoing Trials: (maximum of 2 minutes each)

- ENGOT Ov33/TRUST Manner
- NRG-NACT 007 Moore
- GOG-3015 IMAGYN 050 Moore
- ICON 8b Mcneish
- GINECO/ ENGOT Ov23/ EWOC Pujade
- MITO/ ENGOT Ov32/MITO 23 Lorusso
- ICON 9 Mcneish
- NRG GY005, 009 Moore
- NSGO/ ENGOT Ov24/ AVANOVA PART 3 Mirza
- NSGO/ ENGOT Ov30/UMBRELLA Mirza
- GINECO/ ENGOT Ov29/ATALANTE Kurtz/Pujade
- GINECO/ ENGOT Ov38/OREO Pujade
- AGO/ ENGOT Ov34/ AGO-OVAR 2.29 Harter /Manner
- GEICO/ ENGOT Ov41/ ANITA Gonzalez

Update of Trials in Development (maximum of 3-4 minutes each)

- |                                    |                 |
|------------------------------------|-----------------|
| • AGO/ ENGOT Ov 46/ DUO-O          | Harter / Manner |
| • BGOG/ ENGOT Ov-43/MK7339-01      | Vergote         |
| • GINECO/ ENGOT Ov44/FIRST         | Pujade          |
| • ATHENA                           | Kristeleit/Monk |
| • MITO 25                          | Lorusso/Pignata |
| • NRG-concept OV 1741 NACT +/- ICS | Moore           |
| • NSGO/ ENGOT Ov42/ BAN-ROC        | Mirza           |
| • BGOG/ ENGOT Ov-50/INNOVATE-3     | Vergote         |

New Concepts/Proposals

- |   |           |
|---|-----------|
| • KGOG 3045 / AMBITION (Umbrella)                             | Lee/Kim   |
| • DGOG / OVHIPEC2   | van Driel |
| • NRG Ov 1821 (olaparib-tremelimumab vs olaparib)             | Moore     |
| • NRG Ov 1850 (carbo-paclitaxl-bev vs carbo-mirvetuximab-bev) | Moore     |
| • NRG Ov1846 (NACT with Nivolumab vs Nivolumab & Ipilimumab)  | Moore     |
| • NRG Ov1838 (Copanlisib + olaparib in PS-ROC and PR-ROC)     | Moore     |

Discussion/Future Directions (5 minutes)

Gonzalez/Okamoto

- Strategies that could be used to mentor Young Investigators

ADJOURN